Form 4 - Statement of changes in beneficial ownership of securities
2024年8月22日 - 9:47AM
Edgar (US Regulatory)
SEC Form 4
FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
OMB APPROVAL |
OMB Number: |
3235-0287 |
Estimated average burden |
hours per response: |
0.5 |
|
|
|
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b). |
|
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. |
1. Name and Address of Reporting Person*
1350 AVENUE OF THE AMERICAS |
SUITE 2600 |
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
STANDARD BIOTOOLS INC.
[ LAB ]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X |
Director |
X |
10% Owner |
|
Officer (give title below) |
|
Other (specify below) |
|
|
|
|
|
3. Date of Earliest Transaction
(Month/Day/Year) 08/19/2024
|
4. If Amendment, Date of Original Filed
(Month/Day/Year)
|
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Form filed by One Reporting Person |
X |
Form filed by More than One Reporting Person |
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
1. Title of Security (Instr.
3)
|
2. Transaction Date
(Month/Day/Year) |
2A. Deemed Execution Date, if any
(Month/Day/Year) |
3. Transaction Code (Instr.
8)
|
4. Securities Acquired (A) or Disposed Of (D) (Instr.
3, 4 and 5)
|
5.
Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr.
4)
|
7. Nature of Indirect Beneficial Ownership (Instr.
4)
|
Code |
V |
Amount |
(A) or (D) |
Price |
Common Stock |
08/19/2024 |
|
P |
|
250,000 |
A |
$1.8529
|
52,025,821 |
I |
See footnote
|
Common Stock |
08/20/2024 |
|
P |
|
500,000 |
A |
$1.8734
|
52,525,821 |
I |
See footnote
|
Common Stock |
08/21/2024 |
|
P |
|
500,000 |
A |
$1.9039
|
53,025,821 |
I |
See footnote
|
Common Stock |
|
|
|
|
|
|
|
545,000 |
I |
See footnote
|
Common Stock |
|
|
|
|
|
|
|
13,939,637 |
I |
See footnote
|
Common Stock |
|
|
|
|
|
|
|
2,781,432
|
D
|
|
Common Stock |
|
|
|
|
|
|
|
2,744,219 |
I |
See footnote
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivative Security (Instr.
3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Transaction Date
(Month/Day/Year) |
3A. Deemed Execution Date, if any
(Month/Day/Year) |
4. Transaction Code (Instr.
8)
|
5.
Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
3, 4 and 5)
|
6. Date Exercisable and Expiration Date
(Month/Day/Year) |
7. Title and Amount of Securities Underlying Derivative Security (Instr.
3 and 4)
|
8. Price of Derivative Security (Instr.
5)
|
9.
Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
4)
|
10. Ownership Form: Direct (D) or Indirect (I) (Instr.
4)
|
11. Nature of Indirect Beneficial Ownership (Instr.
4)
|
Code |
V |
(A) |
(D) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
1. Name and Address of Reporting Person*
1350 AVENUE OF THE AMERICAS |
SUITE 2600 |
(Street)
Relationship of Reporting Person(s) to Issuer
X |
Director |
X |
10% Owner |
|
Officer (give title below) |
|
Other (specify below) |
|
|
|
|
|
1. Name and Address of Reporting Person*
1350 AVENUE OF THE AMERICAS |
SUITE 2600 |
(Street)
Relationship of Reporting Person(s) to Issuer
X |
Director |
X |
10% Owner |
|
Officer (give title below) |
|
Other (specify below) |
|
|
|
|
|
1. Name and Address of Reporting Person*
1350 AVENUE OF THE AMERICAS |
SUITE 2600 |
(Street)
Relationship of Reporting Person(s) to Issuer
X |
Director |
X |
10% Owner |
|
Officer (give title below) |
|
Other (specify below) |
|
|
|
|
|
1. Name and Address of Reporting Person*
1350 AVENUE OF THE AMERICAS |
SUITE 2600 |
(Street)
Relationship of Reporting Person(s) to Issuer
X |
Director |
X |
10% Owner |
|
Officer (give title below) |
|
Other (specify below) |
|
|
|
|
|
1. Name and Address of Reporting Person*
1350 AVENUE OF THE AMERICAS |
SUITE 2600 |
(Street)
Relationship of Reporting Person(s) to Issuer
X |
Director |
|
10% Owner |
|
Officer (give title below) |
|
Other (specify below) |
|
|
|
|
|
1. Name and Address of Reporting Person*
1350 AVENUE OF THE AMERICAS, SUITE 2600 |
|
(Street)
Relationship of Reporting Person(s) to Issuer
X |
Director |
|
10% Owner |
|
Officer (give title below) |
|
Other (specify below) |
|
|
|
|
|
1. Name and Address of Reporting Person*
1350 AVENUE OF THE AMERICAS |
SUITE 2600 |
(Street)
Relationship of Reporting Person(s) to Issuer
X |
Director |
|
10% Owner |
|
Officer (give title below) |
|
Other (specify below) |
|
|
|
|
|
1. Name and Address of Reporting Person*
1350 AVENUE OF THE AMERICAS |
SUITE 2600 |
(Street)
Relationship of Reporting Person(s) to Issuer
X |
Director |
|
10% Owner |
|
Officer (give title below) |
|
Other (specify below) |
|
|
|
|
|
1. Name and Address of Reporting Person*
1350 AVENUE OF THE AMERICAS |
SUITE 2600 |
(Street)
Relationship of Reporting Person(s) to Issuer
X |
Director |
|
10% Owner |
|
Officer (give title below) |
|
Other (specify below) |
|
|
|
|
|
Explanation of Responses: |
Remarks: |
|
Casdin Partners Master Fund, LP, By: Casdin Partners GP, LLC, its General Partner, By: /s/ Eli Casdin, Managing Member |
08/21/2024 |
|
/s/ Eli Casdin, Eli Casdin |
08/21/2024 |
|
Casdin Capital LLC, By: /s/ Eli Casdin, Managing Member |
08/21/2024 |
|
Casdin Partners GP LLC, By: /s/ Eli Casdin, Managing Member |
08/21/2024 |
|
Casdin Private Growth Equity Fund II, L.P., By: Casdin Private Growth Equity Fund II GP, LLC, its General Partner, By: /s/ Eli Casdin, Managing Member |
08/21/2024 |
|
Casdin Private Growth Equity Fund GP II, LLC, By: /s/ Eli Casdin, Managing Member |
08/21/2024 |
|
Casdin Private Growth Equity Fund, L.P., By: Casdin Private Growth Equity Fund GP, LLC, its General Partner, By: /s/ Eli Casdin, Managing Member |
08/21/2024 |
|
Casdin Amplify Fund, LP, By: Casdin Partners GP, LLC, its General Partner, By: /s/ Eli Casdin, Managing Member |
08/21/2024 |
|
Casdin Private Growth Equity Fund GP, LLC, By: /s/ Eli Casdin, Managing Member |
08/21/2024 |
|
** Signature of Reporting Person |
Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
* If the form is filed by more than one reporting person,
see
Instruction
4
(b)(v). |
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |
Standard BioTools (NASDAQ:LAB)
過去 株価チャート
から 10 2024 まで 11 2024
Standard BioTools (NASDAQ:LAB)
過去 株価チャート
から 11 2023 まで 11 2024